Long COVID-19 [11C]CPPC Study

Completed · Early Phase 1

Conditions studied: COVID Long-Haul

In brief

The goal of this study is to evaluate the safety of using the \[5-cyano-N-(4-(4-\[11C\]Methylpiperazin-1-yl)-2-(Piperidin-1-yl)Phenyl)Furan-2-carboxamide\] (\[11C\]CPPC) radiotracer in positron emission tomography (PET) imaging of people with history of COVID-19 infection, with and without symptoms. The investigators are also interested to see whether use of this radiotracer reveals imaging differences between patients with history of COVID-19 infection and still exhibiting symptoms or healthy patients with history of COVID-19 infection but exhibiting no current symptoms.

Key facts

Study ID

NCT06223971

Run by

Johns Hopkins University

People needed

6

Starts

2024-08-06

Expected to finish

2026-03-31

Last updated by the study team

2026-04-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Have the ability to understand the requirements of the study, provide written informed consent, understand and provide written authorization for the use and disclosure of Protected Health Information (PHI) [per Health Insurance Portability and Accountability Act (HIPAA) Privacy Ruling] and comply with the study procedures.
• Documented history of COVID infection at least 6 - 12 months before enrollment.
• Men and women at least 18 years old.
• Women must have a negative serum pregnancy test and practice an acceptable method of contraception or be of non-childbearing potential (post-menopausal for at least 2 years or who have undergone hysterectomy, oophorectomy or surgical sterilization).
• Geographic accessibility to the study center and the ability to travel to the clinic for study visits.
• Agrees to the visit schedule as outlined in the informed consent.
• Pre-study labs within normal range, or if abnormal, deemed not clinically significant by the site investigator.

You may not qualify if…

• History of recent nosocomial infection.
• History of chronic neurological disorder, such as epilepsy, or structural Central Nervous System (CNS) abnormality such as stroke or arteriovenous malformation.
• History of head trauma with prolonged loss of consciousness (>10 minutes) or any neurological condition including stroke, seizure (excluding childhood febrile seizure), or visible structural abnormality on prior MRI.
• Active or recent (in the past year) substance dependence (drugs-including nicotine, marijuana or alcohol).
• Receipt of any investigational drug, device or biologic within 30 days of administration of study compound.
• Use of anti-inflammatory medications, immunosuppressants, or benzodiazepines within 7 days of administration of study compound.
• Any concomitant medical disease or condition limiting the safety to participate including, but not limited to:
• Coagulopathy
• Active infection
• Contraindications to MRI scanning to include pacemakers, metallic implants/prosthesis or prohibitive claustrophobia, etc.
• Contraindications to PET scanning to include pregnancy, etc.
• Any medical condition that in the opinion of the study investigators would constitute a safety risk to the subject.
• Any radiation exposure in the past calendar year that in combination with the radiation exposure from this study would exceed 5 rem.
• Any history of learning disability or special education (due to the potential to affect performance on neuropsychological testing).

Where it is running

• Johns Hopkins Outpatient Center — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.